Mild cognitive impairment(MCI)is a clinical transitional state between normal aging and dementia,which is considered to be the preclinical stage of Alzheimer's disease(AD).Due to the irreversible nature of the course of AD,and the lack of clinically available therapies to improve or delay the disease progression,the early detection,diagnosis and intervention of MCI are crucial in reducing the incidence of AD and delaying its progression.On one hand,research on biomarkers can serve as the foundation for elucidating the pathological mechanisms underlying the disease.On the oth-er hand,it provides objective evidence for early screening and diagnosis.This paper reviewed the research progress of MCI biomarkers from the cerebrospinal fluid,blood and genetics perspectives with a focus on the analysis and discussion advancements in biomarkers(especially amyloid protein,phosphorylated tau protein)found in cerebrospinal fluid and blood.The study of biomarkers from different sources and pathways has their own advantages and disadvantages.MCI he-matological biomarkers have significant potential for clinical translation with promising research prospects.The standardi-zation of biomarkers is still a major direction in MCI research field.
维普
万方数据
